Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — Among patients with ventricular tachycardia indicated for an implantable cardioverter ...

Baltimore, MD - A report published this week has shown a high rate of ventricular tachycardia (VT) recurrence—as high as 75% at 14 months—in arrhythmogenic right ventricular dysplasia/cardiomyopathy ...

Ventricular tachycardia (VT) ablation should be considered after the first implantable cardioverter defibrillator (ICD) shock in patients with ischemic or nonischemic cardiomyopathy, the PARTITA trial ...

Please provide your email address to receive an email when new articles are posted on . Catheter ablation improved outcomes vs. antiarrhythmic drugs in patients with VT and ischemic cardiomyopathy.

BERLIN, Germany—Performing ventricular tachycardia (VT) ablation before placement of a primary prevention implantable cardioverter-defibrillator (ICD) had a clinical benefit in a selected group of ...

NEW ORLEANS – The Impella 5.0 and 5.5 left ventricular assist device failed to measure up on outcomes when used for high-risk patients undergoing ventricular tachycardia (VT) ablation therapies, ...

Patients with structural heart disease are at risk for life-threatening ventricular tachycardias (VTs). Implantable cardioverter-defibrillators (ICDs) can terminate VT, but often at the cost of ...

Patients with structural heart disease and monomorphic ventricular tachycardia (VT), irrespective of its etiology, can benefit when early first-line catheter ablation is added before implanting an ...

Berlin, Germany – 8 April 2024: The first randomised trial to investigate preventive ablation of a potential arrhythmogenic substrate associated with coronary chronic total occlusion (CTO) in patients ...

SAN FRANCISCO -- Noninvasive stereotactic radiotherapy (RT) for refractory ventricular tachycardia (VT) achieved outcomes similar to catheter ablation with substantially fewer serious adverse events ...

SAN DIEGO, February 17, 2026--(BUSINESS WIRE)--Vektor Medical, a medical technology company transforming cardiac arrhythmia care, today announced the publication of a peer-reviewed study in EP ...